Emerging treatments
Passive antibodies and interferons
In animal models, passive antibodies as well as interferon-alpha and interferon-gamma are protective before or within hours of inoculation but are probably not useful therapies once clinical disease has developed.[40][42] In view of this, they could potentially be useful for post-exposure prophylaxis in humans (for instance, after laboratory exposure) to prevent progression to clinical disease, but they have never been given to humans for this purpose.
Antivirals
Several key enzymes of the yellow fever virus such as helicase and protease are similar to those of other flaviviruses, including hepatitis C virus and dengue virus. Several compounds, including immune response modifiers and diverse inhibitors targeting different viral targets, are in various stages of pre-clinical development; however, none of these will have practical implications for several years.[40][43]
Use of this content is subject to our disclaimer